Results 251 to 260 of about 48,580 (292)

P13

Oral Diseases, 2005
Withdrawn/transferred ...
openaire   +1 more source

A Novel Translocation (17;19)(p13;p13) in a Patient with Acute Myelomonocytic Leukemia

Cancer Genetics and Cytogenetics, 2000
We report on a patient with acute myeloid leukemia (AML M4) and a so far unrecorded translocation (17;19). The leukemia transformed from a myeloproliferative disorder (MPD) and showed a progressive fatal course. Following transformation, all leukemic cells showed an apparently balanced translocation (17;19)(p13;p13). The breakpoint regions harbor genes
R, Brückner, K, Jentsch-Ullrich, A, Franke, P, Wieacker, M, Stumm   +4 more
openaire   +2 more sources

P13

Journal of Nutrition Education and Behavior, 2007
Lisa Diemoz, Lucrecia Farfan-Ramirez, MaryAnn Lagura, Tuline Baykal   +3 more
  +4 more sources

P13

Surgery for Obesity and Related Diseases, 2006
Stephanie F. Yeager, Christopher D. Still, Peter Benotti, Anthony Petrick, William Strodel, Shawn Yoder, Craig Wood   +6 more
openaire   +2 more sources

Kolofon P13

Peripeti
Peripeti eti og for fatterne   TEMAREDAKTION Janicke Branth, Birgitte Hesselaa, Mia Rendix og Mads Thygesen. REDAKTION Erik Exe Christoffersen (ansv.), Janicke Branth, Falk Heinrich, Mads Thygesen, Thomas Rosendal Nielsen, Birgitte Hesselaa, Laura Schultz, Solveig Gade, Michael Eigrved, Jens Christian Lauenstein Led, Thomas David Kragebæk ...
openaire   +1 more source

P13

Nitric Oxide, 2013
Peter Luedike, Ulrike Hendgen-Cotta, Matthias Totzeck, Andreas Schicho, Christos Rammos, Christian Heiss, Jon Lundberg, Eddie Weitzberg, Malte Kelm, Tienush Rassaf   +9 more
openaire   +1 more source

CT-P13 in the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2017
The first biosimilar infliximab, CT-P13 infliximab-dyyb was approved in 2013 by the European Medicines Agency (EMA) and in 2016 by the United States Food and Drug Administration (FDA) and has been used for the treatment of rheumatoid arthritis (RA) for 4 years.
openaire   +2 more sources

A Review of CT-P13: An Infliximab Biosimilar

BioDrugs, 2014
CT-P13 (Remsima™; Inflectra™), a biosimilar of reference infliximab (Remicade(®)), is approved by the European Medicines Agency for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +2 more sources

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Gastroenterology, 2021
Byong Duk Ye, Walter Reinisch, Shomron Ben-Horin   +2 more
exaly  

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

Rheumatology, 2021
Pavel Shesternya, Marek Zawadzki, Piotr Wiland   +2 more
exaly